Articles tagged "Highly-sensitized"

2016 American Transplant Congress
Impact of Angiotensin II Type I Receptor Antibody Positivity in Highly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).
A. Vo,¹ C. Boutsicaris,¹ X. Zhang,² N. Reinsmoen,² J. Choi,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²HLA Laboratory, Cedars-Sinai Medical Center, LA, CA.
Introduction: Angiotensin II type I receptor antibody (AT1R Ab) is a target for non-HLA antibodies. AT1R ab exert direct effects on endothelial and vascular smooth…
2016 American Transplant Congress
Role of Preformed IgM Donor Human Leucocyte Antigen (HLA) Specific Antibodies in HLA Incompatible Renal Transplantation.
A. Andreou, A. Babu, T. Barber, R. Higgins, D. Briggs, D. Mitchell, N. Khovanova, T. Shaikhina, S. Daga.
Renal, University Hospitals Coventry and Wawickshire, Coventry, United Kingdom; Life Sciences, University of Warwick, Coventry, United Kingdom; School of Mathematics and Engineering, University of Warwick, Coventry, United Kingdom.
Introduction: Pre-transplant IgG antibody screening is common due to its established role of predicting rejection and graft survival; the role of pre-formed IgM human leukocyte…
2016 American Transplant Congress
First Experience with Obinutuzumab (Type II Anti-CD20) in Patients with Treatment-Resistant Glomerular Diseases and Antibody-Mediated Rejection.
J. Choi, S. Jordan, A. Vo.
Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: There is extensive experience with rituximab (RTX,Type I anti-CD20) for desensitization (DES) and treatment of ABMR. There is also a comparable experience in treatment…
2016 American Transplant Congress
Alemtuzumab Is Safe and Effective Induction Therapy in Highly Sensitized (HS) Pediatric Patients Undergoing Transplantation.
I. Kim,¹ J. Choi,¹ A. Vo,¹ A. Kang,¹ M. Toyoda,¹ J. Mirocha,² E. Kamil,¹ S. Louie,¹ O. Galera,¹ S. Jordan,¹ D. Puliyanda.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Biostatistics Core, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: Studies show that alemtuzumab, a potent lymphocyte-depleting agent, is well-tolerated in pediatric renal transplantation. We report on the use of alemtuzumab induction in HS…
2016 American Transplant Congress
Initial Experience with the Bacterial Enzyme IdeS® (IgG Endopeptidase) for Desensitization of Highly-HLA Sensitized (HS) Patients.
S. Jordan,¹ J. Choi,¹ X. Zhang,¹ M. Haas,² A. Peng,¹ J. Kahwaji,¹ R. Villicana,¹ A. Vo.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Pathology, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: The IgG degrading enzyme derived from Streptococcus pyogenes (IdeS®) is a 35k-Da cysteine protease that cleaves human IgG molecules at the lower hinge region…
2016 American Transplant Congress
Long-Term Assessment of the Safety and Efficacy of IVIG and Rituximab-Based Desensitization (DES).
J. Choi, J. Kahwaji, A. Vo, S. Louie, A. Kang, A. Peng, R. Villicana, D. Puliyanda, I. Kim, S. Jordan.
Comprehensive Transplantation Center, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: HLA sensitized patients constitute a growing number of ESRD patients with an immunologic barrier to successful transplantation. Desensitization (DES) therapies have emerged to address…
2016 American Transplant Congress
Impact of the New Kidney Allocation System (KAS) on Transplant Rates & Outcomes in Broadly-HLA Sensitized (HS) Patients Transplanted After Desensitization (DES).
A. Vo,¹ X. Zhang,² S. Williamson,¹ K. Myers,¹ N. Reinsmoen,² J. Choi,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ S. Jordan.¹
¹Kidney Transplant, Cedars-Sinai Medical Center, LA, CA; ²HLA Laboratory, Cedars-Sinai Medical Center, LA, CA.
Introduction: HS patients not desensitized (DES) receiving transplants are at risk for ABMR. DES improves transplant rates, but is limited to donor availability. Implementation of…
2015 American Transplant Congress
Outcomes of Eculizumab (ANTI-C5) Therapy for Treatment of Refractory Antiobdy-Mediated Rejection (ABMR) and Thrombotic Microangiopathy (TMA)
P. Wongsaroj,¹ J. Choi,¹ A. Vo,¹ J. Kahwaji,¹ A. Peng,¹ R. Villicana,¹ M. Haas,² S. Jordan.¹
¹Comprehensive Transplant Center, Cedars-Sinai Medical Center, Los Angeles, CA; ²Pathology, Cedars-Sinai Medical Center, Los Angeles, CA.
Introduction: ABMR results from DSA binding to donor endothelium initiating the classical complement pathway. This results in the formation of terminal MAC (C5b-C9) complex and…
2015 American Transplant Congress
Antibodies Directed Against HLA-DQ Are Significantly Associated to Complement Activation In Vitro
J. Arreola-Guerra, A. de Santiago, A. Arvizu, N. Gonzalez-Tableros, M. Lopez, M. Vilatoba, L. Morales-Buenrostro, J. Alberu, N. Castelan.
1Transplantation, 1aNephrology-Mineral Metabolism, Inst Nal de Ciencias Medicas y Nutricion SZ, Mexico City, Distrito Federal, Mexico.
Background: C1q-binding HLA antibodies (HLAabs) have been related to acute rejection and long-term graft loss. The characteristics of these antibodies and factors associated to complement…
2015 American Transplant Congress
Results of ABO Incompatible Liver Transplantation Using a Simplified Protocol at a Single Institution
J. Lee,¹ J. Lee,¹ J. Lee,² M. Kim,¹ M. Ju,¹ G. Choi,¹ J. Choi,¹ S. Kim,¹ D. Joo.¹
¹Department of Surgery, Yonsei University College of Medicine, Seoul, Republic of Korea; ²Department of Surgery, CHA Bundang Medical Center, Bundang, Republic of Korea.
BackgroundABO incompatible (ABOi) living donor liver transplantation (LDLT) has become a feasible option for patients with end-stage liver disease due to development of various desensitization…